EvaCatharinaGuinanMD

Professor of Radiation Oncology, Dana-Farber Cancer Institute and Harvard Medical School

Dr. Guinan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
44 Binney St
# Dana
Boston, MA 02115
Phone+1 617-632-4932

Fax+1 617-632-2095

Boston Children’s Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 1984 - 1986
Dana-Farber Cancer InstituteResidency, Pediatrics, 1982 - 1984
Boston Children’s Hospital/Boston Medical CenterResidency, Pediatrics, 1980 - 1982
Harvard Medical SchoolClass of 1980

PubMed

232 citations
Results of the Cord Blood Transplantation Study (COBLT): Clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematolog...
Joanne Kurtzberg, Vinod K. Prasad, Shelly L. Carter, John E. Wagner, Lee Ann Baxter-Lowe
Blood. 2008-11-15
68 citations
Bone marrow transplantation for myelodysplasia and secondary acute nonlymphoblastic leukemia.
Gregory D. Longmore, Eva C. Guinan, Howard J. Weinstein, R. D. Gelber, Joel M. Rappeport
Journal of Clinical Oncology. 1990-10-01
56 citations
Bone marrow transplantation for children with myelodysplastic syndromes.
Eva C. Guinan, Nancy J. Tarbell, Ramana Tantravahi, Howard J. Weinstein
Blood. 1989-02-01

Journal Articles

The Open Translational Science in Schizophrenia (OPTICS) Project: An Open-Science Project Bringing Together Janssen Clinical Trial and NIMH Data
Eva C Guinan, Joseph S Ross, Adam J Savitz, Nature

Can AI Tools Segment A Cancer Tumor as Well as an Oncologist?May 21st, 2019
Harvard, Dana-Farber AI Challenge Uses Crowdsourcing to Improve Cancer CareApril 18th, 2019
Scientists Are Training the Body to Accept New OrgansJanuary 22nd, 2019
Join now to see all

rBPI21: Development of a novel radiation mitigatorDARPA2012–Present
In Vivo Irradiations With Patients Undergoing Radiation Therapy: DANA Farber CancNational Institute Of Allergy And Infectious Diseases2010–2011
Potential Role of rBPI21 in Ameliorating Radiation Toxicity: A Murine ModelDARPA2008–2011
Ex Vivo Alloanergization To Improve Immunity After Haploidentical TransplantNational Cancer Institute2009–2010
Rbpi21 &Endotoxin-Directed Innate Immunity In Stem Cell TransplantationNational Heart, Lung, And Blood Institute2008–2009
Endotoxin-directed Innate Immunity in Patients Undergoing Hematopoietic Stem Cell TransplantationDana Foundation2007–2009
Clinical CoreNational Cancer Institute2008
Cellular Correction Of Congenital Hematopoietic DisordersNational Heart, Lung, And Blood Institute2000–2002
Centers For Clinical Research On TransplantationDivision Of Blood Diseases And Resources1998–2000
Phase I/II Study Of Pixy 321 For Patients With Marrow Failure SyndromesNational Center For Research Resources1996–1997
Phase I/II Trial Of Pixy-321 For Patients With Amegakarypcytic ThrombocytopeniaNational Center For Research Resources1996
Phase I Study Of Recombinant Human Interleukin 11National Center For Research Resources1996